Article summary
This double-blind, randomised, placebo-controlled feasibility trial (n=60) tested a single 25 mg dose of psilocybin with psychological support for people with treatment-resistant major depression in an NHS setting. Psilocybin reduced depressive symptoms more than placebo at three weeks, with benefits sustained at six weeks, although non-serious adverse events were more frequent with psilocybin.
Continue to the original publication for the complete article.